Drug Gives Big Survival Boost Against Type of Advanced Breast Cancer
Women with HER2-positive tumors gained an average 16 more months of life with Perjeta, study finds (Source: WebMD Health)
Source: WebMD Health - September 29, 2014 Category: Consumer Health News Source Type: news

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests
Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2014 Category: Science Source Type: news

Hopes for new breast cancer drug
A breast cancer drug could extend the lives of patients with an advanced form of the disease by almost five years, a study has found.Women with an aggressive type of cancer which has been traditionally hard to treat could benefit from using perjeta as a combination therapy with chemotherapy and herceptin, researchers said.A trial into the effectiveness of the combination of drugs found that survival among women with previously untreated advanced HER2-positive breast cancer was e (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - September 29, 2014 Category: Nursing Source Type: news

Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
(Mayo Clinic) Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2014 Category: Cancer & Oncology Source Type: news

Trial Confirms That Perjeta Extends Survival In Metastatic Breast Cancer
Perjeta extends survival in patients with Her2 positive breast cancer. Might drugs targeting Her2 be effective in other malignancies? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 29, 2014 Category: Pharmaceuticals Authors: Elaine Schattner Source Type: news

A New Standard of Care in HER2 Breast Cancer
MADRID (MedPage Today) -- Adding two anti-HER2 agents to chemotherapy for metastatic disease increases media survival to almost 5 years. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 29, 2014 Category: Geriatrics Source Type: news

'Unprecedented' Survival of 15 Months Seen in CLEOPATRA'Unprecedented' Survival of 15 Months Seen in CLEOPATRA
Pertuzumab plus trastuzumab adds a 15-month survival benefit in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug Gives Big Survival Boost Against Type of Advanced Breast Cancer
Women with HER2-positive tumors gained an average 16 more months of life with Perjeta, study finds (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 29, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Roche’s Perjeta breast cancer drug shows extended survival benefit
Roche’s breast cancer drug Perjeta (pertuzumab) has shown extended survival benefits in patients with previously untreated HER2-positive metastatic breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 29, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2014 Category: Science Source Type: news

Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Media News)
Source: Roche Media News - September 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
(European Society for Medical Oncology) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 28, 2014 Category: Biology Source Type: news

Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
Roche today announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival (OS) and progression-free survival (PFS) in women with HER2-negative metastatic breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2014 Category: Pharmaceuticals Source Type: news

HER2 in Trastuzumab/Emtansine vs Trastuzumab/DocetaxelHER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel
What group of patients experience enhanced improvement from T-DM1 therapy? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Breast Cancer Market (HER2-, HER2+) Epidemiology Forecast to 2023 in...
MarketOptimizer.org adds “EpiCast Report: Breast Cancer (HER2-, HER2+) – Epidemiology Forecast to 2023” to its store.(PRWeb September 10, 2014)Read the full story at http://www.prweb.com/releases/breast-cancer-her2-her2/market-outlook-to-2023/prweb12158564.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2014 Category: Pharmaceuticals Source Type: news

pCR and Improved Survival in Breast Cancer? pCR and Improved Survival in Breast Cancer?
Dr. Lidia Schapira discusses an analysis of NeoALTTO, which indicates that achieving pCR after neoadjuvant therapy for HER2+ cancer is associated with improved outcomes -- for some more than others. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Early Data for HER2 Breast Ca Vax Promising
SAN FRANCISCO (MedPage Today) -- A cancer vaccine derived from HER2 protein demonstrated safety and preliminary evidence of activity in a randomized trial of patients with breast cancer. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 10, 2014 Category: Geriatrics Source Type: news

'Got It Right': Guidelines for HER2-Negative Breast Cancer'Got It Right': Guidelines for HER2-Negative Breast Cancer
Dr. Kathy Miller says the ASCO guidelines for advanced HER2-negative breast cancer 'got it right,' focusing on HT, sequential chemo agents, and decisions made jointly by doctors and patients. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 5, 2014 Category: Science Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
(University of Texas M. D. Anderson Cancer Center) A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2014 Category: Cancer & Oncology Source Type: news

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 5, 2014 Category: Cancer & Oncology Source Type: news

ASCO Issues HER2-Negative Breast Cancer Guide
(MedPage Today) -- Hormonal therapy and sequential chemotherapy form the basis of systemic treatment for advanced HER2-negative breast cancer, according to a new clinical guideline. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 3, 2014 Category: Geriatrics Source Type: news

New ASCO Guideline for HER2-negative Advanced Breast CancerNew ASCO Guideline for HER2-negative Advanced Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued a new guideline for the treatment of patients with HER2-negative advanced breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Guidelines for HER2-Negative Advanced Breast Cancer (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology has … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 3, 2014 Category: Primary Care Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - September 3, 2014 Category: Cancer & Oncology Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, News, Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says Source: HealthDay Related MedlinePlus Page: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 2, 2014 Category: Consumer Health News Source Type: news

Merrimack begins Phase II HERMIONE trial of MM-302 for breast cancer treatment
US-based Merrimack Pharmaceuticals has started the Phase II HERMIONE trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin) to treat patients with HER2-positive locally advanced or met… (Source: Drug Development Technology)
Source: Drug Development Technology - August 12, 2014 Category: Pharmaceuticals Source Type: news

New immunotherapy approach targets HER2-positive breast cancer
A new technique aimed at harnessing the body’s immune system to attack one of the deadliest forms of breast cancer is being developed by British scientists. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - July 31, 2014 Category: Nursing Source Type: news

What Is HER2 Status and How Does It Relate to...
HER2, which is also called HER2/neu, and HER-2, is the acronym for human epidermal growth factor receptor 2. Knowing your HER2 status is an important part of your diagnosis. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - July 20, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

T-DM1 Storms All Stages of HER2+ Breast CancerT-DM1 Storms All Stages of HER2+ Breast Cancer
Dr. Lidia Schapira discusses the TH3RESA trial and how T-DM1 is strongly active across all stages of HER2-positive breast cancer, offering yet another effective option with low toxicity. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Aggressive breast cancer protein discovered
Conclusion This is a valuable laboratory study that furthers our understanding of the way HER2 may promote the growth, proliferation and spread of breast cancer cells, possibly through the influence of the protein integrin αvβ6. The researchers suggest up to 40% of people with HER2-positive breast cancers may also have a high expression of integrin αvβ6. The discovery that integrin αvβ6 may play a role in mediating the growth and progression of these cancers hopefully opens up new treatment possibilities for people with HER2-positive cancers. As the researchers suggest, their study supports...
Source: NHS News Feed - July 7, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Discovery offers treatment hope for HER2 positive breast cancer
The discovery of a molecule that helps a particularly dangerous form of breast tumour grow and spread could lead to new treatments, suggest UK researchers. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - July 4, 2014 Category: Nursing Source Type: news

New treatment to stop spread of breast cancer
The discovery offers hope for 4,000 women diagnosed per year with HER2-positive breast cancer, who do not respond well to the current treatment, Herceptin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 4, 2014 Category: Consumer Health News Source Type: news

T-DM1 Now Preferred for Progressive HER2 Breast CancerT-DM1 Now Preferred for Progressive HER2 Breast Cancer
T-DM1, a successor to trastuzumab, should be the preferred choice for HER2-positive breast cancer that has progressed despite multiple lines of treatment, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biweekly Combination for HER2-Positive Metastatic Breast CancerBiweekly Combination for HER2-Positive Metastatic Breast Cancer
Will this relatively tolerable combination of big-guns give something more to patients with advanced breast cancer? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

False Negative Results Found in Prognostic Testing for Breast Cancer
A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the U.S. and internationally. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - June 20, 2014 Category: Hospital Management Authors: Donna Dubuc Tags: Press Release Research breast cancer HER2 Norris Cotton Cancer Center Peter Kaufman Source Type: news

New research could provide key to overcoming resistance to HER2 targeted cancer treatments
(Trinity College Dublin) Scientists from Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments. The findings have just been published in leading international, peer reviewed journal: Cancer Research, the most frequently cited cancer journal in the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2014 Category: Global & Universal Source Type: news

Breast Cancer Therapeutics Market Worth $13.1 billion by 2020 Says a...
ReportsnReports.com adds latest report on “Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs” to its...(PRWeb June 07, 2014)Read the full story at http://www.prweb.com/releases/breast-cancer-therapeutic/market-2020-forecasts/prweb11922634.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 8, 2014 Category: Pharmaceuticals Source Type: news

Kadmon initiates Phase Ib/IIa trial of KD019 and Trastuzumab to treat HER2+ breast cancer
US-based Kadmon has started a Phase Ib/IIa trial of KD019, an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in combination with trastuzumab (Herceptin) to treat HER2+ breast cancer metastasized to the brain. (Source: Drug Development Technology)
Source: Drug Development Technology - June 6, 2014 Category: Pharmaceuticals Source Type: news

Angiochem beings Phase II trial of new peptide drug candidate to treat HER2+ breast cancer
Canadian biotechnology firm Angiochem has started a Phase II clinical trial of ANG1005, a novel paclitaxel-peptide drug conjugate, for the treatment of patients with HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 3, 2014 Category: Pharmaceuticals Source Type: news

Certain Breast Cancer Patients May Need Little Treatment After Tumor Removal
Study might provide an option to women with very small HER2-positive tumors Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Medicines, Women's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 2, 2014 Category: Consumer Health News Source Type: news

Study finds risk of recurrence low in smallest HER2+ breast cancer tumors
(Kaiser Permanente) Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2014 Category: Cancer & Oncology Source Type: news

Certain Breast Cancer Patients May Need Little Treatment After Tumor Removal
Study might provide an option to women with very small HER2-positive tumors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 2, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, News, Source Type: news

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab as adjuvant treatment for HER2 positive early breast cancer (Source: GSK news)
Source: GSK news - June 1, 2014 Category: Pharmaceuticals Source Type: news